Table 3.
Independent risk factors for end-stage renal disease in patients with ANCA-associated renal vasculitis.
| Variables | Univariate analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | |
| Sex, males/females | 1.497 (0.539-4.152) | 0.438 | ||
| Age, per 1-yr increase | 0.982 (0.946-1.029) | 0.421 | ||
| WBC, per 100/µL | 0.998 (0.983-1.013) | 0.881 | ||
| Hb, per 1 mg/dL | 0.940 (0.712-1.219) | 0.651 | ||
| CRP, per 1 mg/dL increase | 0.898 (0.772-0.996) | 0.040* | 0.904 (0.774-1.016) | 0.094 |
| BVAS, per 1 unit increase | 0.926 (0.818-1.034) | 0.181 | ||
| renal risk score, per 1 unit increase | 1.648 (1.366-2.087) | <.0001* | 1.723 (1.387-2.302) | <.0001* |
| History of hypotensive drugs, yes/no | 1.482 (0.518-4.241) | 0.465 | ||
| Smoking history, yes/no | 2.254 (0.659-7.709) | 0.185 | ||
| Use of antidiabetic drugs, yes/no | 1.485 (0.184-11.975) | 0.724 | ||
| Use of methylprednisolone pulse, yes/no | 1.225 (0.387-3.880) | 0.726 | ||
| Dose of prednisolone, per 10 mg increase | 1.121 (0.743-1.730) | 0.600 | ||
| Plasmapheresis, yes/no | 1.743 (0.491-6.182) | 0.417 | ||
| Cyclophosphamide, yes/no | 0.692 (0.156-3.078) | 0.614 |
*p < 0.05. BVAS, Birmingham Vasculitis Activity Score; CI, confidence interval; CRP, C-reactive protein; Hb, hemoglobin; HR, hazard ratio; WBC, white blood cell count